Zydus Lifesciences and Dr. Reddy's Laboratories announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India.

Pertuzumab is a critical treatment for HER2 positive breast cancer patients. The biosimilar has been developed in-house by the research team at the Zydus Research Centre (ZRC).

Under the terms of this agreement, Dr. Reddy's will receive semi-exclusive rights from Zydus to co-market the product in India. The product will be marketed by Zydus under the brand name Sigrima™. Dr. Reddy's will market it under the brand name Womab®. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones